A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

CONDITION

Skin

GENDER

Both males and females

AGE GROUP

From 12

and above

STATUS

Recruiting

This is a randomized, double-blind, placebo-controlled, multicenter, parallel-group study in adult and
adolescent subjects with moderate-to-severe AD. Eligible subjects must have a documented history of
inadequate response to topical AD medication(s).

 

Approved By: Bellberry              

Clinical Trial Registry Link: